



## Complete Summary

---

### TITLE

Prenatal care: percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation.

### SOURCE(S)

Physician Consortium for Performance Improvement®. Prenatal care physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Sep. 10 p. [5 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess the percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12- month period who receive anti-D immune globulin at 26-30 weeks gestation.

### RATIONALE

Rh sensitization is a serious complication of pregnancy that places the lives of both mother and child at risk. This complication can be avoided through the prophylactic administration of anti-D immune globulin.\*

\*The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

Antibody tests can be repeated in an unsensitized, D-negative patient at 26-28 weeks gestation. She should also receive anti-D immune globulin prophylactically at that time. In addition, any unsensitized, D-negative patient should receive anti-D immune globulin if she has one of the following conditions or procedures:

- Ectopic gestation
- Abortion (either threatened, spontaneous, or induced)
- Procedure associated with possible fetal-to-maternal bleeding, such as chorionic villus sampling (CVS) or amniocentesis
- Condition associated with fetal-maternal hemorrhage (e.g., abdominal trauma, abruptio placentae)
- Delivery of a D-positive newborn (American Academy of Pediatrics/American College of Obstetricians and Gynecologists [AAP/ACOG])

The US Preventive Services Task Force (USPSTF) recommends the repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks gestation, unless the biological father is known to be Rh (D)-negative. (USPSTF)

## **PRIMARY CLINICAL COMPONENT**

Prenatal care; D (Rh) negative and unsensitized patients; anti-D immune globulin prophylaxis

## **DENOMINATOR DESCRIPTION**

All patients, regardless of age, who are D (Rh) negative and unsensitized who gave birth during a 12-month period, seen for continuing prenatal care (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

## **NUMERATOR DESCRIPTION**

Patients receiving anti-D immune globulin at 26-30 weeks gestation

## **Evidence Supporting the Measure**

### **EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

## **Evidence Supporting Need for the Measure**

### **NEED FOR THE MEASURE**

Variation in quality for the performance measured

### **EVIDENCE SUPPORTING NEED FOR THE MEASURE**

Golden WE, Wells C. Evaluating prenatal care in Arkansas. J Ark Med Soc 2002 Mar;98(9):296-7. [PubMed](#)

## State of Use of the Measure

### STATE OF USE

Current routine use

### CURRENT USE

Internal quality improvement

## Application of Measure in its Current Use

### CARE SETTING

Ambulatory Care  
Physician Group Practices/Clinics

### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

### LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

### TARGET POPULATION AGE

All patients, regardless of age

### TARGET POPULATION GENDER

Female (only)

### STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

## Characteristics of the Primary Clinical Component

### INCIDENCE/PREVALENCE

Unspecified

### ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

### BURDEN OF ILLNESS

Unspecified

## **UTILIZATION**

Unspecified

## **COSTS**

Unspecified

# **Institute of Medicine National Healthcare Quality Report Categories**

## **IOM CARE NEED**

Staying Healthy

## **IOM DOMAIN**

Effectiveness

# **Data Collection for the Measure**

## **CASE FINDING**

Users of care only

## **DESCRIPTION OF CASE FINDING**

All patients, regardless of age, who are D (Rh) negative and unsensitized who gave birth during a 12-month period, seen for continuing prenatal care

## **DENOMINATOR SAMPLING FRAME**

Patients associated with provider

## **DENOMINATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

All patients, regardless of age, who are D (Rh) negative and unsensitized who gave birth during 12-month period, seen for continuing prenatal care

### **Exclusions**

- Documentation of medical reason(s) for patient not receiving anti-D immune globulin at 26-30 weeks gestation.
- Documentation of patient reason(s) for patient not receiving anti-D immune globulin at 26-30 weeks gestation.
- Documentation of system reason(s) for patient not receiving anti-D immune globulin at 26-30 weeks gestation.

## **RELATIONSHIP OF DENOMINATOR TO NUMERATOR**

All cases in the denominator are equally eligible to appear in the numerator

## **DENOMINATOR (INDEX) EVENT**

Clinical Condition  
Encounter  
Therapeutic Intervention

## **DENOMINATOR TIME WINDOW**

Time window brackets index event

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

Patients receiving anti-D immune globulin at 26-30 weeks gestation

### **Exclusions**

None

## **MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Fixed time period

## **DATA SOURCE**

Administrative data  
Medical record

## **LEVEL OF DETERMINATION OF QUALITY**

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

Unspecified

## **Computation of the Measure**

## **SCORING**

Rate

### **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

### **ALLOWANCE FOR PATIENT FACTORS**

Unspecified

### **STANDARD OF COMPARISON**

Internal time comparison

## **Evaluation of Measure Properties**

### **EXTENT OF MEASURE TESTING**

A demonstration project to test the validity and reliability of measures, as well as their usefulness to practicing physicians, was completed by the Arkansas Foundation for Medical Care (AFMC).

### **EVIDENCE FOR RELIABILITY/VALIDITY TESTING**

Golden WE, Wells C. Evaluating prenatal care in Arkansas. J Ark Med Soc 2002 Mar;98(9):296-7. [PubMed](#)

## **Identifying Information**

### **ORIGINAL TITLE**

Measure #1: anti-D immune globulin.

### **MEASURE COLLECTION**

[The Physician Consortium for Performance Improvement® Measurement Sets](#)

### **MEASURE SET NAME**

[Prenatal Care Physician Performance Measurement Set](#)

### **SUBMITTER**

American Medical Association on behalf of the Physician Consortium for Performance Improvement®

### **DEVELOPER**

Physician Consortium for Performance Improvement®

**FUNDING SOURCE(S)**

Unspecified

**COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE**

Ed Hirsch, MD (*Co-Chair*); Stanley Zinberg, MD, MS (*Co-Chair*); Bruce Bagley, MD; Phil Bongiorno; Caryn Davidson; Ruth B. Goldstein, MD; Ronald Keren, MD, MPH; Dale Magee, MD, MS; Richard Hellman, MD, FACP, FACE; Reed E. Pyeritz, MD, PhD, FACP, FACMG; Sam J.W. Romeo, MD, MBA; Allan J. Wilke, MD, MA

Rebecca Kresowik, Consultant; Timothy Kresowik, MD, Consultant

Pam Scarrow, American College of Obstetricians and Gynecologists

Erin O'Brien, American Medical Association; Karen S. Kmetik, PhD, American Medical Association

**FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST**

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

**ENDORSER**

National Quality Forum

**INCLUDED IN**

Ambulatory Care Quality Alliance

**ADAPTATION**

Measure was not adapted from another source.

**RELEASE DATE**

2002 Jan

**REVISION DATE**

2007 Sep

**MEASURE STATUS**

This is the current release of the measure.

This measure updates a previous version: Physician Consortium for Performance Improvement®. Clinical performance measures: prenatal testing. Tools developed

by physicians for physicians. Chicago (IL): American Medical Association (AMA); 2005. 4 p.

## **SOURCE(S)**

Physician Consortium for Performance Improvement®. Prenatal care physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Sep. 10 p. [5 references]

## **MEASURE AVAILABILITY**

The individual measure, "Measure #1: Anti-D Immune Globulin," is published in the "Prenatal Care Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: [www.physicianconsortium.org](http://www.physicianconsortium.org).

For further information, please contact AMA staff by e-mail at [cqi@ama-assn.org](mailto:cqi@ama-assn.org).

## **NQMC STATUS**

This NQMC summary was completed by ECRI on November 25, 2002. The information was verified by the Physician Consortium for Performance Improvement on August 28, 2003. This NQMC summary was updated by ECRI on November 14, 2005. The information was verified by the measure developer on February 16, 2006. This NQMC summary was updated again by ECRI Institute on January 31, 2008.

## **COPYRIGHT STATEMENT**

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American

Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association. All Rights Reserved

## Disclaimer

### **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

